Related Experiment Video
Updated: Jun 26, 2025
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
CAR-T Cell Therapy: Advances in Kidney-Related Diseases
Longyuan Wu1,2,3,4, Youqin Feng1,2,3,4, Yue Huang1,2,3,4
1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background:
Chimeric antigen receptor (CAR)-T cell therapy represents a significant advancement in the field of immunotherapy, providing targeted eradication of abnormal cells through the recognition between CAR and target antigens. This approach has garnered considerable attention due to its promising results in the clinical treatment of hematological malignancies and autoimmune diseases. As the focus shifts toward exploring novel targets and expanding the application of CAR-T cell therapy to solid tumors, including renal malignancies, researchers are pushing the boundaries of this innovative treatment. However, it is crucial to address the observed comorbidities associated with CAR-T cell therapy, particularly nephrotoxicity, due to the superseding release of cytokines and impairment of normal tissue.
Summary:
Our review discusses the research strategies and nephrotoxicity related to CAR-T cell therapy in various kidney-related diseases and provides insights into enhancing investigation and optimization.
Key Messages:
CAR-T cell therapy has captured the attention of researchers and clinicians in the treatment of renal malignancies, multiple myeloma, systemic lupus erythematosus, and acquired immunodeficiency syndrome, which may lead to potential nephrotoxicity as they involve primary or secondary kidney complications. Understanding and summarizing the current research progress of CAR-T cell therapies can provide valuable insights into novel targets and combinations to optimize research models and enhance their clinical value.
Insights
Chimeric antigen receptor (CAR)-T cell therapy shows promise for treating blood cancers and autoimmune diseases. This review examines CAR-T cell therapy
Area of Science:
- Immunotherapy and Cellular Therapy
- Oncology and Nephrology Research
Background:
- Chimeric antigen receptor (CAR)-T cell therapy is a groundbreaking immunotherapy utilizing engineered T cells to target abnormal cells via CAR-antigen recognition.
- This therapy has demonstrated significant success in treating hematological malignancies and autoimmune diseases, prompting exploration into solid tumors like renal malignancies.
- A critical concern is the associated nephrotoxicity, stemming from cytokine release and potential damage to healthy kidney tissues.
Purpose of the Study:
- To review current research strategies for CAR-T cell therapy in kidney-related diseases.
- To analyze the mechanisms and implications of nephrotoxicity associated with CAR-T cell therapy.
- To provide insights for optimizing CAR-T cell therapy research and clinical application, particularly for renal malignancies.
Main Methods:
- Comprehensive literature review of studies on CAR-T cell therapy and nephrotoxicity.
- Analysis of research strategies targeting renal malignancies and other kidney-related conditions.
- Synthesis of findings on cytokine release and tissue damage mechanisms.
Main Results:
- CAR-T cell therapy is being investigated for renal malignancies, multiple myeloma, systemic lupus erythematosus, and acquired immunodeficiency syndrome, all potentially causing kidney complications.
- Understanding the research progress in CAR-T cell therapies is vital for identifying new targets and combinations.
- Nephrotoxicity is a significant comorbidity that requires careful management and further investigation.
Conclusions:
- CAR-T cell therapy offers a promising avenue for treating various diseases with kidney involvement.
- Addressing and mitigating nephrotoxicity is crucial for the safe and effective expansion of CAR-T cell therapy.
- Further research into novel targets, combinations, and optimization strategies is needed to enhance the clinical value of CAR-T cell therapy.
